Abingdon Health Win Best UK Medtech Dealmaker at OBN Annual Awards 2015

Abingdon Health Ltd (“Abingdon” or “the company”), the specialist rapid diagnostic technology company, is pleased to announce it has won the Best UK Medtech Dealmaker at the OBN Annual Awards held on Thursday 1st October, at the Ashmolean Museum in Oxford. The Awards, which are in their 7th year, celebrate outstanding achievement in the UK life sciences sector.

The award, received by CEO Chris Yates, recognises the company’s successful acquisition of the optical detection company Molecular Vision Ltd, as part of its strategy to become a leading technology based diagnostic company.

Abingdon Health is focused on providing rapid and near-patient medical diagnostic testing solutions. The company is developing a multiplexed immunoassay system based on fully disposable medical diagnostics for the rapid testing market. The device uses organic light emitting diodes (OLEDS) and organic photodetectors (OPDs) for versatile and quantitative optical detection in a portable and disposable format.

Chris Yates, Chief Executive of Abingdon Health, commented: “We are delighted to receive this award in recognition of our acquisition of Molecular Vision. The Molecular Vision technology provides Abingdon Health with a great opportunity to build a next generation rapid testing platform that offers portable, connected, cost effective and multiplexed immunoassay testing”.

Enquiries:
Abingdon Health Ltd +44 121 414 5156
Dr. Chris Hand, Chairman
Chris Yates, CEO

Notes to editors
About Abingdon Health – www.abingdonhealth.com
Abingdon Health Ltd is a UK based in vitro diagnostic group focused on developing a range of rapid testing products in the area of hematology oncology. The Company launched its first rapid testing product in March 2015, Seralite®– FLC, the world’s first rapid diagnostic device in multiple myeloma, and is in the process of launching a range of complementary rapid tests. The Company’s core expertise lies in the development, manufacturing and commercialisation of rapid lateral flow immunoassay diagnostics and reader systems. To support its strategic plan Abingdon is currently developing a multiplexed immunoassay rapid testing system based on fully disposable medical diagnostics for the rapid testing market. This device uses organic light emitting diodes (OLEDS) and organic photodetectors (OPDs) for versatile and quantitative optical detection in a portable and disposable format.